News Center

Home page

Peak Report

News reports

Announcement of Jianfeng Group Lin2017 -005 on Subsidiary Obtaining Drug Clinical Trial Approval

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviations: Jianfeng Group Number: Pro 2017-005

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Subsidiaries Obtaining Approval for Drug Clinical Trials

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

1. Summary

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, received the "Drug Clinical Trial Approval Document" (Deoxypodophyllotoxin for Injection, Approval Document No.: 2017L01082 ) and (Deoxypodophyllotoxin, Approval Document No: 2017L01083)(hereinafter collectively referred to as "DPT"). The relevant details are hereby announced as follows:

2. drug basic information content

(I) deoxypodophyllotoxin

drug name: deoxypodophyllotoxin

English name: Deoxypodophyllotoxin

dosage form: bulk drug

application items: domestic Drug Registration

Registration Classification: Chemical Drug Class 1

Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University

Approval Conclusion: "According to the the People's Republic of China Drug Administration Law and relevant regulations, after examination, this product meets the relevant requirements of drug registration and agrees to conduct clinical trials of this product preparation."

(II) deoxypodophyllotoxin for injection

drug name: deoxypodophyllotoxin for injection

English name: Deoxypodophyllotoxin for Injection

dosage form: injection

application items: domestic drug registration

specification: 100mg

registration classification: chemical drugs category 1

applicant: Zhejiang Jianfeng pharmaceutical co., ltd. and China pharmaceutical university

approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements of drug registration and agrees to carry out clinical trials."

Research and Development and Registration of 3. Drugs

DPT Project was established in March 104 by 2012. Jianfeng Pharmaceutical Co., Ltd. is a new anti-tumor drug developed in cooperation with China Pharmaceutical University. The registration classification belongs to Class 1 of chemical drugs. The first DPT clinical trial application submitted by Jianfeng Pharmaceutical was accepted on July 27, 2016 (acceptance numbers: CXHL1600201 Zhejiang, CXHL1600202 Zhejiang). DPT is an alkaloid antineoplastic drug with tentative indications for lung cancer, breast cancer and gastric cancer, which will be finalized based on clinical trial results. As of the date of this announcement, the accumulated research and development investment and other related expenditures of the DPT project of Jianfeng Pharmaceutical Co., Ltd. totaled about 34.12 million yuan.

Market Situation of Similar Drugs in 4.

Currently, the same alkaloid anti-tumor drugs listed in China mainly include paclitaxel, vinorelbine and docetaxel. The main manufacturers of paclitaxel injection include Yangzijiang Pharmaceutical Group Co., Ltd., Beijing Shuanglu Pharmaceutical Co., Ltd., Haizheng Pfizer Pharmaceutical Co., Ltd., etc, the main manufacturers of Vinorelbine include Jiangsu Haosen Pharmaceutical Group Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Haizheng Pfizer Pharmaceutical Co., Ltd., etc., and the main manufacturers of docetaxel injection include Jiangsu Hengrui Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd.

According to IMS database statistics, the global sales of the above three drugs in 2015 were 16.46, 1.07 and 0.669 billion US dollars respectively, totaling 2.422 billion US dollars.

5. products still need to go on the market.

DPT is currently in the approved clinical trial stage. Jianfeng Pharmaceutical will complete the clinical trial according to the requirements of the "Drug Clinical Trial Approval". After the clinical trial is completed, it will declare for production. It can only produce and market after passing the review and approval of CFDA and obtaining the drug production approval.

Impact of 6. on Listed Companies and Risk Tips

The company has obtained the "Drug Clinical Trial Approval" this time, which will not have a significant impact on the company's recent operating results.

Due to the particularity of drug research and development, there are unpredictable risks such as long cycle and many links from clinical trials to commissioning. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

March 22, 2017

More information

The company organized "charity one day donation"

On the morning of October 22, in the lobby on the first floor of Jianfeng Building, all cadres and employees of the group headquarters and subordinate enterprises working in Jianfeng Building participated in the 2021 "Charity Day Donation" activity to offer their love to Jinhua charity. In the next few days, the company's subordinate enterprises also organized "charity one-day donation" activities one after another.

2021

11-01

The company organizes new employee induction training

"Growth is more important than success. I hope everyone can become the backbone and pillars of the peak as soon as possible." On September 2, Yu Jianhong, general manager of the group company, put forward ardent hopes in the face of new employees. On the 2nd and 3rd, the group company organized induction training for new employees recruited in the past year. The group company chairman Jiang Xiaomeng, general manager Yu Jianhong and other leaders and relevant department heads gave lectures to them.

2021

09-13

Daye Peak: Typical Regional Industrial Green Development

On August 23, Huangshi Radio and Television Station broadcast the special program of "Strengthening Overall Planning and Promoting Energy Saving and Emission Reduction in Industrial Field". Daye Jianfeng Cement Company, as a typical enterprise with outstanding achievements in establishing green factories and energy saving and emission reduction in Huangshi area, appeared in the program.

2021

09-01

Yunnan Peak Helps Border Epidemic Prevention and Control

On August 22, Yunnan Peak Cement Company, through the Red Cross Society of Pu'er City and the Epidemic Prevention Headquarters of Pu'er City, donated vacuum insulation pots with a total value of 800000 yuan to the four border counties for the prevention and control of the new coronary pneumonia epidemic in the border area, and supported the prevention and control of the epidemic at the border with practical actions.

2021

09-01

Group Party Committee to Learn "July 1" Important Speech

On August 13, the party committee of the group company held a special meeting to collectively study General Secretary Xi Jinping's important speech at the celebration meeting of the 100 anniversary of the founding of the Communist Party of China, convey the requirements of the party committee at a higher level, and make arrangements for organizing party members of the company to study the "July 1" speech.

2021

08-23

Spike Ranked 2020 China's Top 100 Cement Clinker Production Capacity

Recently, the company received the "2020 China Cement Clinker Production Capacity Top 100" plaque issued by China Cement Network. The ranking of China's top 100 cement clinker production capacity is organized and evaluated by China Cement Network, an authoritative information platform for the domestic cement industry. It is released according to the actual clinker production capacity of each cement enterprise at the end of last year. The company has been ranked in the top 100 list for many consecutive years.

2021

08-23

< 1...8 9 10...61 > 跳转到页